|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||16.22 - 16.44|
|52 Week Range||14.54 - 17.38|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.56%|
After Berkshire Hathaway (BRK) disclosed its investment of $358 million in Teva Pharmaceuticals (TEVA) on February 14, 2018, in a regulatory filing at the end of 4Q17, Wall Street analysts have had a lot to say about the investment. Teva Pharmaceuticals stock rose ~10.5% during the morning of February 15, 2018, before closing at a rise of ~7.7% on the day. The PowerShares International Dividend Achievers Portfolio (PID) rose ~1.3% on February 15, 2018.
Sanofi (SNY) announced its acquisitions of Bioverativ and Ablynx in the last week of January 2018. The Bioverativ acquisition is valued at more than $11.6 billion, while the Ablynx acquisition is worth 3.9 billion euros. In this article, we’ll have a look at Wall Street’s recommendations and target prices following Sanofi’s Bioverativ acquisition announcement.
Enbridge (ENB) is involved in energy transportation in the United States and Canada. Transportation and other services drove the growth in 2016, offset by commodity sales and gas distribution sales. All of these segments fueled growth in 9M17. The Liquids Pipelines, Green Power, and Transmission segments drove growth in 2016, offset by Gas Distribution, Gas Pipelines, and Processing and Energy Services.
By Rushil Dutta (Reuters) - After a decade of easy-money policy that cut bond yields to almost nothing and lifted U.S. stock markets to records, companies that pay big dividends now look among the most ...
On January 29, 2018, Sanofi entered an agreement with Ablynx where Sanofi will acquire all of the outstanding ordinary shares of Ablynx including American depositary shares (or ADSs), warrants, and convertible bonds. Sanofi will acquire Ablynx by purchasing Albynx’s share at a price of 45 euros per share in cash, which is equivalent to an equity value of approximately 3.9 billion euros. Ablynx is a biopharmaceutical company that specializes in the development of Nanobodies.
Novartis’s (NVS) Innovative Medicines segment includes cardio-metabolic products, oncology products, immunology and dermatology products, respiratory products, neuroscience products, and established products. The segment’s contribution is ~67% of NVS’s total revenues.
Sanofi (SNY) reported a growth of 4.7% in revenues at constant exchange rates to 9.05 billion euros, compared with 9.03 billion euros in 3Q16.
In 1H17, Teva Pharmaceutical's (TEVA) CNS (central nervous system) business generated revenues of ~$2.3 billion, or ~16% lower YoY (year-over-year).
In 1H17, Teva Pharmaceutical's (TEVA) generic medicines business generated revenues of ~$6.1 billion, or ~22% higher YoY (year-over-year).
ONEOK (OKE), the general partner and 41% owner of ONEOK Partners, owns one of the country’s premier natural gas liquid systems. The company’s revenue grew 15% in 2016 after falling…
Novartis's Innovative Medicines segment contributed over 67% of NVS's total revenues at nearly $8.3 billion for the quarter.
Stanley Black & Decker's (SWK) PE ratio of 21.1x is pitted against a sector average of 29.3x. The dividend yield of 1.8% is pitted against a sector average of 1.6%.
Sanofi Pasteur, Sanofi’s (SNY) human vaccine business, reported 26.2% revenue growth at constant exchange rates to 1.0 billion euros in 2Q17. Sanofi Pasteur reported growth across all product franchises ...
In 2Q17, Fresenius Medical Care (FMS) reported revenues close to 3.3 billion euros, which represents year-over-year growth of ~11%.
In 2Q17, Sanofi Genzyme (SNY) reported revenue growth of 13.5% to 1.7 billion euros. Considering a constant structure and constant exchange rates, the growth was 14.4%. Sanofi Genzyme, which includes product ...
Analysts expect Novartis's (NVS) revenues to fall ~1.6% to $12.3 billion in 2Q17 due to the effects of the acquisition and divestiture of some of its products.